NYSE:ANVS Annovis Bio (ANVS) Stock Price, News & Analysis → 😱 This phenomenon is smashing regular market gains (From MillPub) (Ad) Free ANVS Stock Alerts $6.11 +0.54 (+9.69%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$5.46▼$6.3150-Day Range$5.52▼$18.0852-Week Range$5.23▼$22.49Volume1.04 million shsAverage Volume421,736 shsMarket Capitalization$67.28 millionP/E RatioN/ADividend YieldN/APrice Target$25.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Annovis Bio alerts: Email Address Annovis Bio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside313.3% Upside$25.25 Price TargetShort InterestBearish13.17% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.06Based on 34 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.35) to ($2.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.07 out of 5 starsMedical Sector565th out of 926 stocksPharmaceutical Preparations Industry247th out of 418 stocks 3.4 Analyst's Opinion Consensus RatingAnnovis Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAnnovis Bio has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.17% of the outstanding shares of Annovis Bio have been sold short.Short Interest Ratio / Days to CoverAnnovis Bio has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Annovis Bio has recently decreased by 3.33%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAnnovis Bio does not currently pay a dividend.Dividend GrowthAnnovis Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANVS. Previous Next 2.8 News and Social Media Coverage News SentimentAnnovis Bio has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 34 news articles for Annovis Bio this week, compared to 2 articles on an average week.Search Interest30 people have searched for ANVS on MarketBeat in the last 30 days. This is an increase of 76% compared to the previous 30 days.MarketBeat Follows16 people have added Annovis Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Annovis Bio insiders have not sold or bought any company stock.Percentage Held by Insiders38.30% of the stock of Annovis Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.83% of the stock of Annovis Bio is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Annovis Bio are expected to grow in the coming year, from ($3.35) to ($2.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Annovis Bio is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Annovis Bio is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Your Bank Account Before It’s Too LateFor months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …Stop right now and do these 3 things to protect yourself About Annovis Bio Stock (NYSE:ANVS)Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.Read More ANVS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANVS Stock News HeadlinesMay 2, 2024 | seekingalpha.comAnnovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into QuestionMay 1, 2024 | americanbankingnews.comAnnovis Bio (NYSE:ANVS) Price Target Lowered to $26.00 at Canaccord Genuity GroupMay 2, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.May 1, 2024 | americanbankingnews.comAnnovis Bio (NYSE:ANVS) Receives Buy Rating from HC WainwrightApril 30, 2024 | seekingalpha.comAnnovis Bio: Searching For Efficacy In Alzheimer's DiseaseApril 30, 2024 | americanbankingnews.comAnnovis Bio Target of Unusually High Options Trading (NYSE:ANVS)April 29, 2024 | finanznachrichten.deAnnovis Bio Inc.: Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer's DiseaseApril 29, 2024 | msn.comS&P 500 Edges Higher; ON Semiconductor Earnings Top ViewsMay 2, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.April 29, 2024 | marketwatch.comAnnovis Bio Shares Sink After Buntanetap Study Misses EndpointApril 29, 2024 | bizjournals.comAnnovis Bio stock price plummets following mixed results for experimental Alzheimer's treatmentApril 29, 2024 | msn.comWhy Is Alzheimer's-Focused Annovis Bio Stock Nosediving On Monday?April 29, 2024 | msn.comAnnovis Bio tumbles 53% on data for Alzheimer's candidate buntanetapApril 29, 2024 | finance.yahoo.comUPDATE 2-Annovis tumbles as Alzheimer's treatment misses in mid-stage studyApril 29, 2024 | finance.yahoo.comAnnovis Bio Shares Tumble After Drug Candidate Buntanetap for Alzheimer's Misses Efficacy Endpoint in Phase 2/3 StudyApril 29, 2024 | reuters.comAnnovis Bio reports positive results in mid-stage Alzheimer's treatment trialApril 29, 2024 | globenewswire.comAnnovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer's DiseaseApril 17, 2024 | finance.yahoo.comIntra-Cellular (ITCI) Up as Depression Drug Meets Study GoalsApril 4, 2024 | msn.comAnnovis Bio Makes Strides in Neurodegenerative Disease Treatment: 2023 Q4 Results Below Projections, Progress Seen in Clinical TrialsApril 3, 2024 | msn.comAnnovis Bio's Buntanetap Shows Promise in Early Alzheimer’s Disease StudyApril 2, 2024 | markets.businessinsider.comBuy Rating Reiterated for Annovis Bio Amid Anticipated Positive Trial Results for Alzheimer’s and Parkinson’s TreatmentsApril 2, 2024 | investorplace.comANVS Stock Earnings: Annovis Bio Misses EPS for Q4 2023April 2, 2024 | globenewswire.comAnnovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial ResultsApril 1, 2024 | globenewswire.comAnnovis Announces Publication That Supports Understanding of Buntanetap's Mechanism of Action in HumansMarch 24, 2024 | msn.comAnnovis Bio Nears Milestone in Alzheimer’s Treatment Study with Completion of Data CleaningMarch 21, 2024 | marketwatch.comAnnovis Bio Shares Up 31% on Progress Toward Reporting Data From Alzheimer's StudyMarch 20, 2024 | marketwatch.comAnnovis Bio Completes Data Cleaning for Buntanetap StudySee More Headlines Receive ANVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Annovis Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/29/2024Today5/02/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:ANVS CUSIPN/A CIK1477845 Webwww.annovisbio.com Phone610-727-3913FaxN/AEmployees6Year FoundedN/APrice Target and Rating Average Stock Price Target$25.25 High Stock Price Target$36.00 Low Stock Price Target$9.00 Potential Upside/Downside+313.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($6.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-56,200,000.00 Net MarginsN/A Pretax Margin-74,496.43% Return on Equity-446.06% Return on Assets-257.97% Debt Debt-to-Equity RatioN/A Current Ratio2.39 Quick Ratio2.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.73) per share Price / Book-8.37Miscellaneous Outstanding Shares11,011,000Free Float6,794,000Market Cap$67.28 million OptionableOptionable Beta1.59 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Maria L. Maccecchini Ph.D. (Age 73)Founder, CEO, President & Executive Director Comp: $965.6kMr. Henry Hagopian III (Age 56)M.B.A., Chief Financial Officer Comp: $510.05kDr. Cheng Fang Ph.D.Senior Vice President of Research & DevelopmentMs. Eve M. Damiano M.S.RAC, Senior Vice President of Regulatory OperationsMs. Melissa GainesSenior Vice President of Clinical OperationsKey CompetitorsKezar Life SciencesNASDAQ:KZRCalciMedicaNASDAQ:CALCKronos BioNASDAQ:KRONJaguar HealthNASDAQ:JAGXEledon PharmaceuticalsNASDAQ:ELDNView All CompetitorsInstitutional OwnershipWealthspire Advisors LLCBought 990 shares on 2/7/2024Ownership: 0.104%Merit Financial Group LLCSold 19,000 shares on 2/6/2024Ownership: 0.210%View All Institutional Transactions ANVS Stock Analysis - Frequently Asked Questions Should I buy or sell Annovis Bio stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Annovis Bio in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ANVS shares. View ANVS analyst ratings or view top-rated stocks. What is Annovis Bio's stock price target for 2024? 4 analysts have issued 1 year price targets for Annovis Bio's stock. Their ANVS share price targets range from $9.00 to $36.00. On average, they anticipate the company's stock price to reach $25.25 in the next twelve months. This suggests a possible upside of 313.3% from the stock's current price. View analysts price targets for ANVS or view top-rated stocks among Wall Street analysts. How have ANVS shares performed in 2024? Annovis Bio's stock was trading at $18.70 on January 1st, 2024. Since then, ANVS shares have decreased by 67.3% and is now trading at $6.11. View the best growth stocks for 2024 here. Are investors shorting Annovis Bio? Annovis Bio saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,500,000 shares, an increase of 11.1% from the March 15th total of 1,350,000 shares. Based on an average daily trading volume, of 268,500 shares, the short-interest ratio is currently 5.6 days. View Annovis Bio's Short Interest. When is Annovis Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ANVS earnings forecast. How were Annovis Bio's earnings last quarter? Annovis Bio, Inc. (NYSE:ANVS) announced its quarterly earnings results on Friday, March, 29th. The company reported ($1.09) earnings per share (EPS) for the quarter. What other stocks do shareholders of Annovis Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Annovis Bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), KushCo (KSHB), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Auxly Cannabis Group (CBWTF), Novan (NOVN), Sorrento Therapeutics (SRNE), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF). When did Annovis Bio IPO? Annovis Bio (ANVS) raised $10 million in an initial public offering on Wednesday, January 29th 2020. The company issued 1,400,000 shares at $6.00-$8.00 per share. ThinkEquity (a division of Fordham Financial Management, Inc. ) acted as the underwriter for the IPO. Who are Annovis Bio's major shareholders? Annovis Bio's stock is owned by a number of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Claudine Bruck, Maria-Luisa Maccecchini and Reid Mccarthy. View institutional ownership trends. How do I buy shares of Annovis Bio? Shares of ANVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:ANVS) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics😱 This phenomenon is smashing regular market gainsMillPubYour bank is lying to you.MyBankTrackerDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
